A study to learn how vamorolone affects the body, how safe it is and how it moves into, through and out of the body in healthy male participants

2024-512101-60-00 Protocol SNT-I-VAM-026 Human pharmacology (Phase I) - Other Ended

Start 5 Jun 2024 · End 6 Jul 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol SNT-I-VAM-026

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 30
Countries 1
Sites 1

Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

Key facts

Sponsor
Santhera Pharmaceuticals (Schweiz) AG, Santhera Pharmaceuticals (Schweiz) AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
5 Jun 2024 → 6 Jul 2024
Decision date (initial)
2024-05-06
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

VersionLevelCodeTermSystem organ class
20.0 PT 10013801 Duchenne muscular dystrophy 100000004850
20.0 PT 10059117 Becker's muscular dystrophy 100000004850

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Santhera Pharmaceuticals (Schweiz) AG

Sponsor organisation
Santhera Pharmaceuticals (Schweiz) AG
Address
Hohenrainstrasse 24
City
Pratteln
Postcode
4133
Country
Switzerland

Scientific contact point

Organisation
Santhera Pharmaceuticals (Schweiz) AG
Contact name
Catherine Dutreix

Public contact point

Organisation
Santhera Pharmaceuticals (Schweiz) AG
Contact name
Santhera General Inquiries

Santhera Pharmaceuticals (Schweiz) AG

Sponsor organisation
Santhera Pharmaceuticals (Schweiz) AG
Address
Hohenrainstrasse 24
City
Pratteln
Postcode
4133
Country
Switzerland

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 30 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Nuvisan GmbH
Clinical Services, Wegenerstrasse 13, Ludwigsfeld, Neu-Ulm

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-06-05 2024-07-06 2024-06-05 2024-06-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-14 Germany Acceptable
2024-04-30
2024-05-06